Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25487988 | 0.80 | KDM4E (0.54) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL12986264 | 0.79 | MAPT (0.52) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL13193606 | 0.79 | KDM4E (0.52) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL25487380 | 0.79 | KDM4E (0.52) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL8144149 | 0.76 | MAPT (0.61) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL15824088 | 0.76 | KDM4E (0.55) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL22895336 | 0.76 | KDM4E (0.48) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL29661896 | 0.75 | MAPT (1.00) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL1085388 | 0.75 | MAPT (1.00) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 | |
| SCHEMBL30609418 | 0.75 | KDM4E (0.47) | MAPTMEN1KMT2AHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | CELGENE CAR LLC (BM) | 2023-05-23 | — | — | US | disclosed |
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | CELGENE CAR LLC (BM) | 2023-05-23 | — | — | US | disclosed |
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| US-20220259222-A1 | MK2 INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | CELGENE CORPORATION | 2022-08-18 | — | — | US | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| US-20210139501-A1 | MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-13 | — | — | US | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-01-30 | — | — | US | disclosed |
| WO-2012140243-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012140243-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012137181-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012137181-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2012-10-11 | — | — | WO | disclosed |
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | POLRMT, MAVS, EIF2AK2 | MAPT 2074/4885MEN1 4591/4885KMT2A 2560/4885 |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | MAPT 3230/4885MEN1 580/4885KMT2A 647/4885 |
| US-20220259222-A1 | MK2 INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | WEE2, MAPKAPK2, WEE1 | MAPT 3263/4885MEN1 1835/4885KMT2A 353/4885 |
| US-11584757-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAPT 2354/4885MEN1 2025/4885KMT2A 377/4885 |
| US-20210139501-A1 | MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | WEE2, WEE1, CDK2 | MAPT 2157/4885MEN1 1195/4885KMT2A 168/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | MAPT 3230/4885MEN1 580/4885KMT2A 647/4885 |
| US-11655257-B2 | MK2 inhibitors, synthesis thereof, and intermediates thereto | WEE2, WEE1, CDK2 | MAPT 2157/4885MEN1 1195/4885KMT2A 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.